Rituximab, the first anti‐CD20 monoclonal antibody, has dramatically improved outcomes for
patients with B‐cell lymphoproliferative disorders. Obinutuzumab was developed to …

Patients with chronic lymphocyticleukemia (CLL) typically have innate/adaptive immune
system dysregulation, thus the protective effect of coronavirus disease 2019 (COVID-19) …

Patients with hematological malignancies have an increased risk of serious outcomes
following COVID-19 infection, suggesting broader protection is needed beyond vaccination …

Ibrutinib, the first in class of the oral covalent Bruton tyrosine kinase (BTK) inhibitors, has
profoundly changed the treatment landscape of chronic lymphocytic leukemia (CLL). The …

ABSTRACT Background Coronavirus disease 2019 (COVID-19), an acute, sometimes
severe respiratory illness caused by a novel coronavirus has led to a vast pandemic with an …

Abstract Coronavirus disease 2019 (COVID-19) is first detected in December 2019 in
Wuhan, China which is a new pandemic caused by SARS-COV-2 that has greatly affected …

Main aim of this systematic review is to quantify the risk and identify predictors of clinical
evolution of SARS‐CoV‐2 in hematological patients compared to different control …

Background: The clinical presentation of coronavirus disease 19 (COVID-19) is the result of
intricate interactions between the novel coronavirus and the immune system. In patients with …

Significance between time points with missing values was assessed using Kruskal-Wallis
test with Dunn's posttest. Correlation analysis was done using non-parametric Spearman …

The Omicron variant of SARS-CoV-2 has rapidly become the dominant strain worldwide due
to its high transmissibility, although it appears to be less pathogenic than previous strains …